Glycine transporter-1 inhibitor, N-methyglycine (sarcosine), added to clozapine for the treatment of schizophrenia

doi:10.1016/j.biopsych.2006.04.005

機構典藏 > College of Sciences > Graduate Institute & Department of Mathematics > Journal Article > Item 987654321/41652

Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/41652

Title:	Glycine transporter-1 inhibitor, N-methyglycine (sarcosine), added to clozapine for the treatment of schizophrenia
Authors:	Lane, Hsien-yuan;Huang, Chieh-liang;Wu, Po-lun;Liu, Yi-ching;張玉坤;Chang, Yue-cune;張玉坤;Lin, Pao-yen;Chen, Po-wei;Tsai, Guochuan
Contributors:	淡江大學數學學系
Keywords:	Glutamate;GlyT-1;N-methyl-D-aspartate;sarcosine;schizophrenia;treatment
Date:	2006-09-15
Issue Date:	2010-01-28
Publisher:	Elsevier
Abstract:	Background Agonists at the N-methyl-D-aspartate (NMDA)-glycine site (D-serine, glycine, D-alanine and D-cycloserine) and glycine transporter-1 (GlyT-1) inhibitor (N-methylglycine, or called sarcosine) both improve the symptoms of stable chronic schizophrenia patients receiving concurrent antipsychotics. Previous studies, however, found no advantage of D-serine, glycine, or D-cycloserine added to clozapine. The present study aims to determine the effects of sarcosine adjuvant therapy for schizophrenic patients receiving clozapine treatment. Methods Twenty schizophrenic inpatients enrolled in a 6-week double-blind, placebo-controlled trial of sarcosine (2 g/day) which was added to their stable doses of clozapine. Measures of clinical efficacy and side-effects were determined every other week. Results Sarcosine produced no greater improvement when co-administered with clozapine than placebo plus clozapine at weeks 2, 4, and 6. Sarcosine was well tolerated and no significant side-effect was noted. Conclusions Unlike patients treated with other antipsychotics, patients who received clozapine treatment exhibit no improvement by adding sarcosine or agonists at the NMDA-glycine site. Clozapine possesses particular efficacy, possibly related to potentiation of NMDA-mediated neurotransmission. This may contribute to the clozapine’s unique clinical efficacy and refractoriness to the addition of NMDA-enhancing agents.
Relation:	Biological Psychiatry 60(6), pp.645-649
DOI:	10.1016/j.biopsych.2006.04.005
Appears in Collections:	[Graduate Institute & Department of Mathematics] Journal Article

Files in This Item:

File	Description	Size	Format
		0Kb	Unknown	346	View/Open
index.html		0Kb	HTML	107	View/Open

Loading...